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Background: The purpose of this study was to compare the efficacy and safety of argon laser 
peripheral iridoplasty (ALPI) and systemic intraocular pressure (IOP)-lowering medications in 
the immediate management of acute phacomorphic angle closure.
Methods: Consecutive cases of acute phacomorphic angle closure were randomized to receive 
ALPI and an intravenous or oral carbonic anhydrase inhibitor as initial treatment. Intravenous 
mannitol was administered for presenting IOP . 60 mmHg or IOP . 40 mmHg 2 hours post-
treatment in both arms.
Results: Of 10 consecutive cases, six received medical therapy and four received ALPI. Fifty 
percent in the medical group and none in the ALPI group required intravenous mannitol. 
The ALPI group took less time to achieve IOP , 25 mmHg (18.8 ± 7.5 minutes versus 
115.0 ± 97.0 minutes, P = 0.001, F test); had a greater IOP reduction within 30 minutes 
(69.8% ± 7.7% versus 40.9 ± 23.9%, P = 0.03, t-test); and had a consistently smaller post-attack 
cup to disc ratio (0.50 ± 0.02 versus 0.60 ± 0.20, P = 0.002, F test).
Conclusion: ALPI offers greater safety, consistency, and efficacy than systemic IOP-lowering 
medications as initial treatment for phacomorphic angle closure.
Keywords: phacomorphic, glaucoma, argon laser peripheral iridoplasty, medical, intraocular 
pressure
Introduction
Acute phacomorphic angle closure is a secondary angle closure resulting from a rapid 
increase in the anterior-posterior diameter of a mature cataract. This causes closure of 
the drainage angle and an acute elevation of intraocular pressure (IOP).1 Treatment 
includes lowering the IOP with medications and removing the cause by cataract 
extraction.1 Urgent treatment is important because persistent high IOP can result in 
permanent closure of the angle as well as irreversible optic nerve damage.2–4
Conventional medical treatment includes use of a systemic carbonic anhydrase 
inhibitor or a hyperosmolar agent, together with topical cycloplegic and antiglaucoma 
eye drops. Systemic carbonic anhydrase inhibitors are known to have many side effects, 
including metabolic acidosis, Stevens-Johnson syndrome, and blood dyscrasias.5–9 
Systemic hyperosmotic agents can cause electrolyte disturbances, pulmonary edema, 
and congestive heart failure.10
However, medical treatment may fail to control IOP, and definitive treatment by 
cataract extraction can be risky in the acute phase because of corneal edema and 
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elevated IOP. Recently, argon laser peripheral iridoplasty 
(ALPI) has been used to open up the angle in acute pri-
mary angle closure by placing a ring of laser burns on the 
peripheral iris to contract the iris stroma near the angle. 
This will open up the angle, thus lowering the IOP and 
allowing the eye to become quiet before definitive cataract 
extraction is performed. The usual practice is to perform 
ALPI 3–6 hours after maximal medications fail to control 
the IOP.11–13 In acute primary angle closure, previous studies 
have demonstrated ALPI to be an effective and safe imme-
diate treatment, avoiding the use of systemic IOP-lowering 
medications altogether.14–17 ALPI may work as effectively in 
acute phacomorphic angle closure.
The current practice of attempting maximal systemic anti-
glaucomatous treatments first may not be optimal, because 
those who fail to respond to medical treatment will have 
prolonged nerve damage from the persistent high IOP, and 
elderly patients may not be able to tolerate the side effects of 
the systemic carbonic anhydrase inhibitor and hyperosmotic 
agent. On the other hand, ALPI may be able to lower the IOP 
within a shorter time by mechanically opening up the drain-
age channels. The potential downsides include inflammation 
with high powers, possible synechial closure, and technical 
difficulties and inadvertent corneal damage in a shallow 
anterior chamber.
The objective of this study was to investigate whether or 
not ALPI is superior to traditional systemic antiglaucomatous 
medications in the immediate management of phacomorphic 
angle closure.
Materials and methods
This was a prospective, randomized, controlled study con-
ducted at a district hospital in Hong Kong Special Admin-
istrative Region, People’s Republic of China. Consecutive 
cases of acute phacomorphic angle closure were recruited 
from December 2009 to December 2010.
Acute phacomorphic angle closure was diagnosed by the 
presence of an intumescent cataract and signs of acute angle 
closure, including conjunctival injection, shallow anterior 
chamber, corneal edema in the index eye, and/or an open 
angle in the contralateral eye as determined by gonioscopy. 
The study received approval from the ethics committee of the 
hospital authority and followed the Declaration of Helsinki. 
There was no proprietary interest in the study.
Inclusion criteria were age $ 18 years and ability to 
give informed consent, first acute attack of phacomorphic 
angle closure, and IOP . 40 mmHg. Exclusion criteria were 
IOP-lowering treatment received prior to the study, corneal 
opacity preventing laser treatment to the peripheral iris, and 
an uncooperative patient.
Snellen best corrected visual acuity (BCVA), dura-
tion of symptoms, gonioscopy, and IOP were recorded at 
baseline. All patients received one drop of atropine 1% eye 
drops (Alcon Inc, Hünenberg, Switzerland) and one drop 
of timolol 0.5% eye drops (Santen Pharmaceutical Co, Ltd, 
Osaka, Japan) immediately after the diagnosis was made. 
The patients were randomized into two groups by an inde-
pendent party, whereby the ALPI group received immediate 
ALPI and the medical group received systemic IOP-lowering 
medication. All treatments were delivered within one hour 
of presentation. In each group, if IOP was .60 mmHg on 
presentation, 200 mL of 20% intravenous mannitol was 
administered over one hour under cardiac monitoring. All 
IOPs were measured with Goldman applanation tonometry 
by a single investigator.
The ALPI group received ALPI under topical anesthesia 
with amethocaine 1% (Alcon Inc, Hünenberg, Switzerland). 
The laser beam was focused onto the peripheral iris as close 
to the limbus as possible, using an Abraham contact lens. 
All four quadrants (360o) were treated. The laser energy was 
titrated until the end point was reached when localized iris 
contraction under area of treatment was visible.
The medical group received 500 mg of intravenous aceta-
zolamide. These patients continued to take acetazolamide 
250 mg four times daily and Slow-K® (Novartis, East Hanover, 
NJ) 600 mg twice daily orally until IOP was normalized. 
Unlike in acute primary angle closure, laser peripheral 
iridotomy is not routinely performed for phacomorphic 
angle closure at our center because the aim of phacomorphic 
angle closure is to remove the intumescent cataract as soon 
as possible after achieving reasonable corneal clarity. Laser 
peripheral iridotomy may induce greater inflammation and 
cause zonular loosening, both delaying and making the 
cataract extraction more difficult.
After commencement of treatment, the IOP was measured 
at 15 minutes, 30 minutes, one hour, and hourly until it was 
below 25 mmHg, and measured on day 1 posttreatment. In 
each group, if the IOP remained .40 mmHg at 2 hours, 
200 mL of 20% intravenous mannitol would be administered 
over one hour, if not already given. The ALPI group would 
also receive oral acetazolamide 250 mg four times daily 
and Slow-K 600 mg twice daily if the above conditions 
were met.
In both groups, the treated eye was maintained on 1% 
atropine daily, timolol 0.5% twice daily, and Pred Forte 1% 
4–6 times per day (Allergan Inc, Irvine, CA) until definitive 
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cataract extraction was performed by one of the three glau-
coma surgeons at our center. Atropine is given to relieve the 
pupil block caused by anterior bulging of the intumescent 
cataract and to facilitate cataract extraction later on.
Definitive treatment with cataract extraction and intraocu-
lar lens insertion was performed within 72 hours after IOP 
control. Specular microscopy was performed for both eyes 
of each patient at 3 months after the attack. BCVA was mea-
sured one month after cataract extraction. Gonioscopy and 
ultrasound biomicroscopy (Paradigm Medical Industries Inc, 
Salt Lake City, UT) were performed at 3 months post attack. 
Stratus optical coherence tomography (Carl Zeiss Meditec 
Inc, Dublin, CA) was used for retinal nerve fiber layer and 
optic nerve head analyses at 3 and 9 months post attack.
During the preliminary outcome assessment, the investiga-
tors decided to terminate the study prematurely as a result of 
the clinically significant differences in outcome between the 
two treatment groups and the disproportionate number of sub-
jects requiring intravenous mannitol in the medical group.
Statistical comparisons between the ALPI and medical 
group were performed using a t-test with Welch correction. 
Given the limitation in sample size as a result of early termi-
nation of the study, we anticipated that statistical significance 
may not be apparent, so we also supplemented our analysis 
with the F test for unequal variance. A statistically significant 
F test would also be able to validate that the two populations 
had different outcomes from the two treatments. All means 
were expressed as the mean ± standard deviation. Statistical 
significance was defined as P , 0.05.
Results
Ten consecutive cases were included in the study. All 
patients were of Chinese ethnicity. Six cases (two male and 
four female) received medical therapy (three right eyes and 
three left eyes). Four cases (one male and three female) 
received ALPI (one right eye and three left eyes). The mean 
patient age was 79.7 ± 7.2 years in the medical group and 
78.3 ± 11.0 years in the ALPI group. The mean present-
ing IOP was 50.7 ± 8.4 mmHg in the medical group and 
50.3 ± 6.9 mmHg in the ALPI group. The mean duration 
of the attack was 2.8 ± 3.5 days in the medical group and 
0.9 ± 0.25 days in the ALPI group based on the history of 
symptom duration. For the presenting BCVA, the medical 
group had three cases with hand movement and three with 
light perception, whilst the ALPI group had one case with 
hand movement and three cases with light perception.
In the medical group, 50% (3/6) required intravenous 
mannitol, due to one case presenting with IOP . 60 mmHg 
and two cases of IOP . 40 mmHg after 2 hours of treatment 
with the systemic carbonic anhydrase inhibitor. There were 
no serious adverse effects from the systemic IOP-lowering 
medications. None of the cases in the ALPI group required 
intravenous mannitol. All ALPI procedures were performed 
by a single surgeon within 5–10 minutes in the manner 
described above, with a mean of 54.5 ± 14.8 laser shots. 
There were no complications from ALPI.
Fifteen minutes after treatment, the mean IOP reduction 
from presentation in the medical group was 20.0 ± 14.0 mmHg 
(40.0% ± 27.4%) and 33.8 ± 10.9 mmHg (67.7% ± 20.9%) 
in the ALPI group. At 30 minutes, the mean IOP reduction 
was 20.8 ± 5.5 mmHg (40.9% ± 23.9%) in the medical group 
and 34.8 ±1.6 mmHg (69.8% ± 7.7%) in the ALPI group. At 
one hour, the mean IOP reduction was 15.5 ± 24.0 mmHg 
(37.0% ± 31.6%) in the medical group and 34.7 ± 3.2 mmHg 
(64.5% ± 4.3%) in the ALPI group. At 2 hours, the mean IOP 
reduction was 24.3 ± 17.4 mmHg (46.4% ± 29.1%) in the 
medical group and 31.7 ± 4.0 mmHg (66.0% ± 11.8%) in the 
ALPI group. At day 1 posttreatment, the mean IOP reduction 
was 33.7 ± 8.2 mmHg (68.7% ± 6.6%) in the medical group 
and 33.5% ± 9.6% mmHg (66.8% ± 16.5%) in the ALPI 
group. All eyes in the ALPI group had IOP , 25 mmHg 
within 30 minutes of treatment (see Figure 1).
The mean time taken to reduce the presenting IOP 
to ,25 mmHg was 115.0 ± 97.0 minutes in the medical 
group and 18.8 ± 7.5 minutes in the ALPI group (t-test 
P = 0.06, F test P = 0.001, see Figure 2) The mean percent-
age of IOP reduction from presentation in the ALPI group 
(69.8% ± 7.7%) was significantly greater than in the medical 
group (40.9% ± 23.9%) at 30 minutes posttreatment (t-test 
P = 0.03, F test P = 0.09, see Figure 3).
One day after treatment, all cases in each group achieved 
a clear cornea and IOP , 21 mmHg  in the medical group (on 
oral acteazolamide and timolol 0.5%) and with a mean IOP of 
15.8 ± 4.2 mmHg in the medical group and 16.7 ± 9.0 mmHg 
in the ALPI group  (on timolol 0.5% alone) (t-test P = 0.9, F 
test P = 0.1). The medical group had cataract extraction done 
at a mean of 1.7 ± 0.8 days after the initial treatment and the 
ALPI group had cataract extraction done 1.3 ± 0.5 days after 
the initial treatment.
All cases in both groups received extracapsular cataract 
extraction and intraocular lens without any intraoperative 
complications, but one case from the medical group required a 
scleral fixation intraocular lens due to lens subluxation one week 
postoperatively. There was no documented trauma history.
The postoperative mean BCVA was 0.4 ± 0.2 in both 
groups. At 3 months, the IOP without medication for the 
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Figure 2 Time taken to lower iOP to ,25 mmHg.
Abbreviations: ALPi, argon laser peripheral iridoplasty; iOP, intraocular pressure.
medical group was 11.2 ± 4.2 mmHg and 9.5 ± 2.3 mmHg for 
the ALPI group (t-test P = 0.4, F test P = 0.4). At 9 months, 
the mean IOP was 11.2 ± 3.3 mmHg in the medical group 
and 11.5 ± 3.1 mmHg in the ALPI group (t test P = 0.7, F 
test P = 1.0). One case in the medical group required topical 
antiglaucoma medication to maintain IOP , 21 mmHg.
The mean degree of peripheral anterior synechiae formation 
at 3 months was 45.0° ± 45.3° and 22.5° ± 45.0° in the medi-
cal group and ALPI group, respectively (t-test P = 0.5, F test 
P = 1.0). The mean trabecular-iris angle by ultrasound biomi-
croscopy was 35.9° ± 4.6° and 38.8° ± 3.6° in the medical group 
and ALPI group, respectively (t-test P = 0.2, F test P = 0.9).
The mean endothelial cell count for the medical 
group was 1928.5 ± 529.1 cells/mm2 at 3 months and 
2318.2 ± 887.7 cells/mm2 in the uninvolved contralateral 
eye. In the ALPI group, the mean endothelial cell count was 
2379.3 ± 573.3 cells/mm2 and 2509 ± 694.6 cells/mm2 in the 
contralateral eye. There was no significant difference between 
the two groups (t-test P = 0.3, F test P = 0.8).
Mean retinal nerve fiber layer thickness for the medical 
group was 88.7 ± 21.6 µm at 3 months and 78.3 ± 20.5 µm 
at 9 months. Mean retinal nerve fiber layer thickness in the 
contralateral eye of the medical group measured at 3 months 
was 101.0 ± 22.3 µm. For the ALPI group, mean retinal nerve 
fiber layer thickness layer was 102.9 ± 24.4 µm at 3 months 
and 96.1 ± 19.1 µm at 9 months. Mean retinal nerve fiber 
layer thickness in the contralateral eye was 105.0 ± 20.0 µm 
when measured at 3 months. There were no significant dif-
ferences in retinal nerve fiber layer thickness between the 
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Figure 1 Percentage of iOP reduction following treatment.
Abbreviations: ALPi, argon laser peripheral iridoplasty; iOP, intraocular pressure.
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Figure 3 Amount of IOP reduction within the first 30 minutes of treatment.
Abbreviations: ALPi, argon laser peripheral iridoplasty; iOP, intraocular pressure.
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two treatment arms at either 3 or 9 months (t-test P . 0.2, 
F test P . 0.8). The 3-month mean cup to disc ratio by 
optical coherence tomography analysis of the optic nerve 
head was 0.60 ± 0.20 and 0.50 ± 0.02 in the medical group 
and ALPI group, respectively (t-test P = 0.2, F test = 0.002, 
see Table 1).
Discussion
Tham et al have established ALPI to be effective in 
IOP-lowering for phacomorphic angle closure, reducing 
the IOP by 19.3% in the first 15 minutes, with the only 
contraindications being poor endothelial function and eyes 
with flat anterior chambers.16 The question that remains unan-
swered is how does ALPI compare with traditional systemic 
medical therapy?
In our study comparing the safety and efficacy of medical 
therapy versus ALPI, both groups had similar presenting IOP 
of .50 mmHg, but the amount and rate of IOP decrease was 
more pronounced in the ALPI group.
The mean time taken to reduce the presenting IOP 
to ,25 mmHg was 115 (range 15–240) minutes when using 
systemic medication, but only 19 (range 15–30) minutes 
when using ALPI alone. Within the first 30 minutes, there 
was a significantly greater IOP reduction in the ALPI group 
(69%, IOP reduction range 32–38 mmHg) compared with 
the medical group (41%, IOP reduction range 6–46 mmHg). 
Thus, ALPI not only offered close to 30% more IOP reduc-
tion compared with medical therapy within just 30 minutes 
of treatment, but produced more consistent results with less 
variability. In addition, the mean IOP reduction at all time 
points on treatment day was greater in the ALPI group. Even 
one day after treatment, the ALPI group was able to sustain 
an IOP reduction of 67%, similar to that in patients in the 
medical group who were receiving oral acetazolamide. Thus, 
ALPI may be able to replace the use of systemic acetazol-
amide in phacomorphic angle closure.
In terms of safety, 50% of those receiving intravenous and 
oral carbonic anhydrase inhibitors eventually required intra-
venous mannitol to lower their IOP further. As a precaution, 
all intravenous mannitol was given under continuous cardiac 
monitoring. Although no serious systemic complications 
were noted from the systemic medications, hyperosmolar 
agents may not be suitable for all elderly patients, especially 
those with pre-existing renal impairment, pulmonary edema, 
or congestive heart failure. None of the ALPI-treated patients 
required supplementary intravenous mannitol. There were 
no side effects from the ALPI, apart from faint laser marks 
on the peripheral iris, visible only on slit-lamp examination. 
Table 1 Comparison between medical therapy versus ALPi
Medical therapy (n = 6) ALPI (n = 4)
Mean age 79.7 ± 7.2 years 78.3 ± 11.0 years
Mean presenting iOP 50.7 ± 8.4 mmHg 50.25 ± 6.9 mmHg
Presenting VA HM to LP HM to LP
Mean duration of phacomorphic angle closure 2.8 ± 3.5 days 0.9 ± 0.25 days
Mean percentage reduction of iOP 15 mins after treatment 40.0% ± 27.4% 67.7% ± 20.9%
Mean percentage reduction iOP 30 mins after treatment 40.9% ± 23.9% 69.8% ± 7.7%
Mean percentage reduction iOP 60 mins after treatment 37.0% ± 31.6% 64.5% ± 4.3%
Mean percentage reduction iOP 120 mins after treatment 46.4% ± 29.1% 66.0% ± 11.8%
Mean percentage reduction iOP 1 day after treatment 68.7% ± 6.6% 66.8% ± 16.5%
Mean iOP at Day 1 after treatment 15.8 ± 4.2 mmHg 16.7 ± 9.0 mmHg
Percent requiring iV mannitol 50% 0
Mean time from treatment to cataract extraction 1.7 ± 0.8 days 1.3 ± 0.5 days
Mean iOP at 3 months after attack 11.2 ± 4.2 9.5 ± 2.3 mHg
Mean iOP at 9 months after attack 11.2 ± 3.3 mmHg 11.5 ± 3.1 mmHg
Precent requiring topical glaucoma medication 16.7% 0
Mean BCVA at 1 month after attack 0.4 ± 0.2 0.4 ± 0.2
Mean angle at 3 months after attack 35.9° ± 4.6° 38.8° ± 3.6°
Mean PAS at 3 months after attack 45.0° ± 45.3° 22.5° ± 45.0°
Mean endothelial count at 3 months after attack 1928.5 ± 529.1 
cells/mm2
2379.3 ± 573.3 
cells/mm2
Mean RnFL at 3 months after attack 88.7 ± 21.6 um 102.9 ± 24.4 um
Mean RnFL at 9 months after attack 78.3 ± 20.5 um 96.1 ± 19.1 um
Mean CDR by OCT 3 months after attack 0.6 ± 0.2 0.5 ± 0.02
Abbreviations: ALPi, argon laser peripheral iridoplasty; BCVA, best-corrected visual acuity; CDR, cup-to-disc ratio; HM, hand movement; LP, light perception; OCT, optical 
coherence tomography; RNFL, retinal nerve fiber layer; PAS, peripheral anterior synechiae; IV, intravenous; IOP, intraocular pressure; VA, visual acuity.
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Both groups achieved a normalized IOP and clear cornea to 
allow for uneventful cataract extractions within 1–2 days of 
presentation.
Postoperatively, one case in the medical group required 
scleral fixation of an intraocular lens due to subluxation one 
week postoperatively. This lens subluxation was likely to 
be due to zonular loosening because there was no history of 
trauma postoperatively. The mean BCVA was 0.4 in both 
groups.
Both groups had open angles at 3 months via gonios-
copy and ultrasound biomicroscopy, but the ALPI group 
had 50% less peripheral anterior synechiae formation as 
compared with the medical group, possibly due to prompter 
angle opening during the laser-induced contractions of the 
peripheral iris. The postoperative IOP at 3 and 9 months was 
comparable, with a mean difference of less than 2 mmHg in 
both treatment arms. Only one case belonging to the medi-
cal group required topical glaucoma medication to maintain 
IOP , 21 mmHg.
In both groups, the post-attack endothelial cell count 
was lower compared with that in the uninvolved eye, which 
can be used as a proxy measure of the pre-attack state for 
each individual. We were unable to obtain any pre-attack 
endothelial cell counts because all cases presented only dur-
ing phacomorphic attack. The mean endothelial count in the 
medical group (1928 cells/mm2) was slightly lower than that 
in the ALPI group (2379 cells/mm2).
The majority of the patients in this study were unable 
to produce reliable Humphrey visual field assessments. 
Using optical coherence tomography for assessment of the 
optic nerve head, we found a smaller mean cup to disc ratio 
of 0.5 (range 0.47–0.50) in the ALPI group and 0.6 (range 
0.39–0.94) in the medical group, with much greater variability 
in the medical group. Both treatment arms had a thinner mean 
retinal nerve fiber layer as compared with the contralateral eye, 
which can be used as a proxy measure of the pre-attack state. 
However, in the medical group, the mean retinal nerve fiber 
layer seemed to be thinner compared with that in the ALPI 
group at both 3 and 9 months following the attack.
Our study had a limited sample size due to its early 
termination for safety and ethical reasons. Due to the dra-
matic difference in time taken to lower the presenting IOP 
to ,25 mmHg (115 minutes in the medical group versus 
19 minutes in the ALPI group), the percentage of patients 
requiring intravenous mannitol (50% in the medical group 
versus 0% in the ALPI group), and the amount of IOP lower-
ing within 30 minutes of treatment (41% in medical group 
versus 69% in the ALPI group), the investigators concluded 
that it would be unethical to continue this study just to achieve 
a greater statistical significance in data whilst subjecting 
patients to a slower IOP reduction and the unnecessary 
adverse effects of systemic medical therapy. Although we 
were just short of demonstrating a statistically significant dif-
ference in the mean time taken to lower IOP to ,25 mmHg 
(P = 0.06, t-test), the finding of a statistically significant 
difference in variance (P = 0.001, F test) was just as impor-
tant in validating a difference in outcome between the two 
treatment arms. Similarly, a difference of 0.1 in the cup to 
disc ratio detected on optical coherence tomography may not 
be of much clinical significance, but what the difference in 
variance signifies is that ALPI delivered more consistency 
in achieving a lower cup to disc ratio overall compared with 
the medical group, in which the post-attack cup to disc ratio 
outcome was more variable. We postulate that the individual 
physiological response to systemic medication can vary. 
Whilst some patients respond rapidly, others may take longer, 
giving rise to greater variability in IOP lowering and less 
predictable glaucomatous optic nerve damage, as reflected 
by a more variable cup to disc ratio post attack. However, for 
ALPI, the effect is primarily mechanical, hence the response 
and outcome is not only rapid but consistent for all treated 
patients in terms of degree of IOP reduction, time taken to 
normalize IOP, and post-attack cup to disc ratio.
There was a slight difference in presentation time 
between the medical group (2 days) and the ALPI group 
(one day). However, given that the treatment was random-
ized and previous studies have documented good outcomes 
for presentations less than 5 days,17 this minor difference 
in presentation is negligible because the presenting IOP in 
both treatment arms was similar and both groups were able 
to achieve normalization of IOP and corneal clarity one day 
posttreatment.
To the best of our knowledge, this is the first trial directly 
comparing ALPI versus conventional systemic medication for 
the immediate management of phacomorphic angle closure. 
The advantages of ALPI are that it: generates a more consis-
tent, rapid, and greater reduction of IOP to ,25 mmHg within 
30 minutes of treatment; avoids use of systemic carbonic 
anhydrase inhibitors and hyperosmotic agents; produces a 
consistently smaller cup to disc ratio post attack; and achieves 
a comparable post-attack visual acuity, endothelial cell count, 
angle status, retinal nerve fiber layer thickness, and IOP when 
compared with medical therapy. Immediate ALPI may be 
utilized in phacomorphic angle closure as a safer, more rapid, 
and more consistent modality of IOP reduction in place of 
systemic IOP-lowering medications.
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